US5770198A
(en)
*
|
1988-05-18 |
1998-06-23 |
The Research Foundation Of The State Of New York |
Platelet-specific chimeric 7E3 immunoglobulin
|
US5169930A
(en)
*
|
1990-01-05 |
1992-12-08 |
La Jolla Cancer Research Foundation |
Fibronectin receptor
|
US7132260B2
(en)
*
|
1991-04-05 |
2006-11-07 |
The General Hospital Corporation |
DNA encoding parathyroid hormone receptor
|
DE69233472T2
(de)
*
|
1991-04-05 |
2006-02-09 |
The General Hospital Corp., Charlestown |
Parathormonrezeptor und dafür codierende DNA
|
US7150974B1
(en)
|
1991-04-05 |
2006-12-19 |
The General Hospital Corporation |
Parathyroid hormone receptor binding method
|
SG52262A1
(en)
*
|
1993-01-08 |
1998-09-28 |
Tanabe Seiyaku Co |
Peptide inhibitors of cell adhesion
|
US6955900B1
(en)
*
|
1993-02-02 |
2005-10-18 |
The Scripps Research Institute |
Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
|
US5753230A
(en)
*
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
US6056958A
(en)
*
|
1994-12-09 |
2000-05-02 |
Dupont Pharmaceuticals |
Method of treatment of arterial and venous thromboembolic disorders
|
DE69531187T2
(de)
*
|
1994-12-20 |
2004-04-22 |
Merck Patent Gmbh |
Monoklonaler Antikörper gegen das Alpha-V-Integrin
|
US5817768A
(en)
*
|
1995-06-07 |
1998-10-06 |
The New York Blood Center, Inc. |
Monospecific antibodies against a subunit of fibrinogen
|
SK163598A3
(en)
|
1996-05-31 |
1999-06-11 |
Scripps Research Inst |
Methods and compositions useful for inhibition of angiogenesis
|
WO1998009651A1
(fr)
*
|
1996-09-03 |
1998-03-12 |
Chugai Seiyaku Kabushiki Kaisha |
COMPLEXES D'ANTICORPS ANTI-INTEGRINE α3
|
EP0846702B1
(de)
*
|
1996-12-09 |
2009-03-11 |
MERCK PATENT GmbH |
Löslicher, rekombinanter alphaV beta3 Adhäsionsrezeptor
|
US6590079B2
(en)
*
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
US20010011125A1
(en)
*
|
1997-01-30 |
2001-08-02 |
William D. Huse |
Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
|
EP1491632A3
(de)
|
1997-03-12 |
2006-01-04 |
Smithkline Beecham Corporation |
Anti-alphavbeta3 humanizierte monoklonale Antikörper
|
AU6954498A
(en)
*
|
1997-04-11 |
1998-11-11 |
G.D. Searle & Co. |
Methods for using antagonistic anti-avb3 integrin antibodies
|
ATE225670T1
(de)
*
|
1997-04-11 |
2002-10-15 |
Searle & Co |
Antagonistische anti-avb3 integrin antikörper
|
US6210904B1
(en)
*
|
1997-10-14 |
2001-04-03 |
Merck & Co., Inc. |
Anticoagulant test
|
DE19828068C2
(de)
*
|
1998-06-24 |
2003-12-18 |
Peter Dietsch |
Mittel zur spezifischen Hemmung osteoklastärer Knochenresorption
|
CA2338283A1
(en)
*
|
1998-08-13 |
2000-02-24 |
G.D. Searle & Co. |
Multivalent avb3 and metastasis-associated receptor ligands
|
EP1135688A2
(de)
*
|
1998-12-04 |
2001-09-26 |
Novartis AG |
Verfahren und zusammensetzungen zur gezielten bindung an den alpha(nu)-beta(3) vitronectin rezeptor
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US7049140B1
(en)
|
1999-04-29 |
2006-05-23 |
Vanderbilt University |
X-ray guided drug delivery
|
US6159443A
(en)
*
|
1999-04-29 |
2000-12-12 |
Vanderbilt University |
X-ray guided drug delivery
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
US6037176A
(en)
*
|
1999-06-25 |
2000-03-14 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of integrin beta 3 expression
|
EP1235595B8
(de)
*
|
1999-09-08 |
2009-10-07 |
Bayer Schering Pharma Aktiengesellschaft |
Integrin-vermittelte arzneimittel-zielrichtung
|
JP4307775B2
(ja)
*
|
1999-10-28 |
2009-08-05 |
ゼイェトホサイン・アハリネヤート |
Csf−1インヒビターの使用
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
ES2260234T3
(es)
*
|
2000-05-12 |
2006-11-01 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
Utilizacion de inhibidores del factor de crecimiento placentario para el tratamiento de la angiogenesis patologica, de la arteriogenesis patologica, de la inflamacion, de la formacion tumoral y/o de la perdida vascular.
|
US7163681B2
(en)
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US7220824B1
(en)
|
2000-08-28 |
2007-05-22 |
Bayer Aktiengesellschaft |
Integrin-mediated drug targeting
|
EP1219305A1
(de)
*
|
2000-12-27 |
2002-07-03 |
Bayer Aktiengesellschaft |
Konjugate von Integrinrezeptorantagonisten und einem zytostatischen Mittel mit spezifisch spaltbaren Linkergruppen
|
CA2439852A1
(en)
*
|
2001-03-02 |
2002-09-12 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
US7306925B2
(en)
|
2001-11-09 |
2007-12-11 |
Vanderbilt University |
Phage antibodies to radiation-inducible neoantigens
|
US20050084489A1
(en)
*
|
2002-03-04 |
2005-04-21 |
Wilder Ronald L. |
Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
|
CA2478239A1
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
|
WO2003086458A1
(en)
*
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
US20050186204A1
(en)
*
|
2002-06-28 |
2005-08-25 |
Peter Carmeliet |
Use of antibodies against FLT-1 for the treatment of osteoporosis
|
AU2003251728A1
(en)
*
|
2002-06-28 |
2004-01-19 |
K.U.Leuven Research & Development |
Placental growth factor as a target for the treatment of osteoporosis
|
WO2004066956A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
KR20110094361A
(ko)
*
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
WO2005044978A2
(en)
*
|
2003-07-15 |
2005-05-19 |
Washington University |
Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
|
US7271245B2
(en)
*
|
2004-02-13 |
2007-09-18 |
The Scripps Research Institute |
Methods and compositions for inhibition of metastasis
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
EP1755660B1
(de)
*
|
2004-05-07 |
2010-03-24 |
The University of North Carolina at Chapel Hill |
Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
|
US8187595B2
(en)
|
2004-05-07 |
2012-05-29 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
|
BRPI0510915A
(pt)
|
2004-06-04 |
2007-11-13 |
Genentech Inc |
método para o tratamento da esclerose múltipla e artigo manufaturado
|
JP2008518023A
(ja)
|
2004-10-27 |
2008-05-29 |
メディミューン,インコーポレーテッド |
同族抗原に対する親和性を改変することによる抗体特異性の調節
|
DK1869085T3
(da)
*
|
2005-03-24 |
2012-06-18 |
Thrombogenics Nv |
Hidtil ukendt anti-PLGF-antistof
|
US7867490B2
(en)
*
|
2005-06-30 |
2011-01-11 |
Vib Vzw |
Treatment of liver cirrhosis and its complications
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
WO2008011216A2
(en)
*
|
2006-05-16 |
2008-01-24 |
Pro-Pharmaceuticals, Inc. |
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
|
WO2008008373A2
(en)
|
2006-07-11 |
2008-01-17 |
Arubor Corp |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
WO2008016431A2
(en)
*
|
2006-07-29 |
2008-02-07 |
Robert Lamar Bjork |
Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
|
DK2068889T3
(da)
|
2006-08-10 |
2020-02-03 |
Roy C Levitt |
Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
JP5522717B2
(ja)
*
|
2008-09-19 |
2014-06-18 |
国立大学法人佐賀大学 |
アトピー性皮膚炎の検出方法および予防・治療剤のスクリーニング方法
|
MX2011003428A
(es)
|
2008-10-02 |
2011-07-29 |
Vib Vzw |
Inhibicion del factor de crecimiento placentario (plgf) para tratar la leucemia con cromosoma filadelfia positivo.
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20110256055A1
(en)
*
|
2008-12-23 |
2011-10-20 |
Ge Healthcare Limited |
Application of 99mtc peptide-based compound as a bone marrow imaging agent
|
EP2396036B1
(de)
|
2009-02-13 |
2017-06-28 |
Immunomedics, Inc. |
Immunokonjugate mit einer intrazellulär spaltbaren verknüpfung
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
IN2012DN03354A
(de)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
CA2831572C
(en)
|
2011-05-02 |
2019-11-26 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
WO2013079713A1
(en)
|
2011-12-01 |
2013-06-06 |
Thrombogenics Nv |
Improving trabeculectomy outcome
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
MX2014009043A
(es)
|
2012-01-31 |
2014-10-14 |
Genentech Inc |
Anticuerpos anti-ige y sus metodos de uso.
|
CN104379169A
(zh)
|
2012-08-14 |
2015-02-25 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
US9073996B2
(en)
*
|
2012-08-31 |
2015-07-07 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
|
DK2900277T3
(da)
|
2012-12-13 |
2022-04-04 |
Immunomedics Inc |
Doser af immunokonjugater af antistoffer og sn-38 til forbedret effektivitet og reduceret toksicitet
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
WO2014130648A1
(en)
|
2013-02-20 |
2014-08-28 |
Galectin Therapeutics, Inc. |
Method for treatment of pulmonary fibrosis
|
MX2016010683A
(es)
|
2014-02-21 |
2017-05-11 |
Ibc Pharmaceuticals Inc |
Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
EP3160504B1
(de)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
|
EP3172222A4
(de)
|
2014-07-24 |
2018-03-21 |
Washington University |
Gegen strahlungsinduzierte moleküle gerichtete zusammensetzungen und verfahren zur verwendung davon
|
WO2016057398A1
(en)
|
2014-10-07 |
2016-04-14 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
AU2016252771B2
(en)
|
2015-04-22 |
2021-12-16 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
CN107735104B
(zh)
|
2015-06-25 |
2022-05-03 |
免疫医疗公司 |
组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
多発性硬化症を治療するための方法
|
EP3207937A1
(de)
|
2016-02-17 |
2017-08-23 |
Royal College of Surgeons in Ireland |
Verfahren zur behandlung oder prävention von sepsis
|
KR102101561B1
(ko)
*
|
2018-07-25 |
2020-04-20 |
가톨릭대학교 산학협력단 |
신생혈관 표적용 조영제 조성물 및 이의 제조방법
|
CN113557246B
(zh)
*
|
2019-07-24 |
2023-09-01 |
韩国基础科学支援研究院 |
靶向αvβ3整联蛋白的单域抗体
|
CA3208998A1
(en)
|
2021-01-22 |
2022-07-28 |
Steven Kerrigan |
Treatment of coronavirus
|
WO2022239720A1
(ja)
|
2021-05-10 |
2022-11-17 |
公益財団法人川崎市産業振興財団 |
抗原への結合親和性を低減させた抗体
|